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Available online 15 June 2016Rationale: Eslicarbazepine acetate (ESL) is a once-daily oral antiepileptic drug for the treatment of partial-onset sei-
zures. Adverse events such as dizziness and somnolence reported in clinical studies suggest that ESL has detectable
central nervous system (CNS) effects in addition to its antiepileptic effects. This Phase I study evaluated the abuse
liability of ESL compared with that of alprazolam (ALP) and placebo (PBO) in recreational CNS depressant users.
Methods: In this single-dose, randomized, double-blind, PBO- and active-controlled crossover study, healthy recre-
ational CNS depressant userswho could discern betweenALP 2mg and PBO received single oral doses of each of the
following treatmentswith awashout interval of ≥7 days between each treatment: ESL (800mg, 1600mg, 2000mg,
and 2400 mg); ALP (1.5 mg and 3.0 mg); and PBO. Subjective measures, including visual analog scales (VASs)
e.g., Drug-Liking (primary endpoint), and Addiction Research Center Inventory (ARCI) Morphine–Benzedrine
Group (MBG), Pentobarbital Chlorpromazine Alcohol Group (PCAG), and Lysergic Acid Diethylamide Group scales
were evaluated at multiple time points up to 24 h postdose. Cognitive effects were evaluated using the Choice Re-
action Time (CRT), Divided Attention (DAT) and Hopkins Verbal Learning Task—Revised tests.
Principal results: Peak scores for Drug-Liking VAS (maximum effect [Emax]) were signiﬁcantly higher for both ALP
doses than for PBO (p b 0.0001), thereby conﬁrming study validity. Drug-Liking VAS Emax was signiﬁcantly lower
for all ESL doses than both ALP doses (p b 0.0001). Drug-Liking VAS Emax for ESL 800 mg was similar to that for
PBO (least squares [LS] mean difference: 3.6; p = 0.19). At the three higher ESL doses (1600 mg and the
supratherapeutic doses of 2000 mg and 2400 mg), Drug-Liking VAS Emax was signiﬁcantly higher than for PBO, al-
though thedifferenceswereminimal (LSmeandifference: 9.3–13.3 out of 100). Formost secondary subjective end-
points (i.e., Good Effects VAS and High VAS, ARCI-MBG, Take Drug Again VAS, Overall Drug-Liking VAS, and ARCI-
PCAG; p b 0.05), the effect of ESL (all doses)was signiﬁcantly less than that of ALP (both doses). Onmost secondary
measures, the dose–response relationship was relatively ﬂat or showed saturation at higher ESL doses. Although
signiﬁcant differenceswere observed for ESL comparedwith those for PBO for some speciﬁc CRT andDATendpoints
(i.e., reaction time,manual tracking, hit latency), ALP demonstrated signiﬁcant and dose-dependent impairment on
the majority of cognitive endpoints when compared with PBO and ESL. Mean plasma concentrations of the active
metabolite of ESL, eslicarbazepine, increased with increasing ESL dose. Pharmacokinetic parameters estimated for
eslicarbazepine were generally comparable with results from previous studies in healthy volunteers.
Conclusion: This study demonstrated that single doses of ESL may have less abuse liability than ALP in recreational
sedative users. Although ESL had detectable subjective effects and showed some drug-‘liking’ at higher doses, the
magnitude of these effects was small.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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(AED), approved by the US Food and Drug Administration (FDA) for
the treatment of partial-onset seizures (POS) as monotherapy or
adjunctive therapy. Eslicarbazepine acetate is approved by the
European Medicines Agency as adjunctive therapy of POS in adults
and by Health Canada as adjunctive therapy of POS in patients with ep-
ilepsywhose seizures are not satisfactorily controlledwith conventional
therapy. Following oral administration, ESL is extensively converted to
the active metabolite eslicarbazepine [1], which is thought to act
primarily by stabilizing the inactivated state of voltage-gated sodium
channels and delaying its return to the resting state, thus leading to
inhibition of repetitive neuronal ﬁring [2]. The efﬁcacy and safety of
ESL as adjunctive therapy and as monotherapy in patients with POS
have been demonstrated in Phase III studies [3–9].
Adverse events (AEs) recorded in Phase III clinical studies of ESL in-
cluded dizziness, headache, and somnolence [3,5,7–9] suggesting that
ESL has detectable central nervous system (CNS) effects in addition to
its effects as anAED. As such, a premarket assessment of abuse potential,
which included a review of the chemistry, pharmacology, animal
behavior, pharmacokinetics, and safety data for ESL, was required as
per the FDA Guidance on the Assessment of Abuse Potential of Drugs
[10]. Results frompreclinical abuse liability studies, including a drug dis-
crimination study in rhesus monkeys, demonstrated that ESL does not
induce benzodiazepine-like subjective effects. However, based on its
CNS AE proﬁle in Phase I to Phase III studies, a human abuse liability
studywas conducted. The purpose of the studywas to evaluate possible
abuse-related effects of therapeutic and supratherapeutic single oral
doses of ESL compared with those of placebo (PBO) and alprazolam
(ALP), a scheduled drug with sedative effects (i.e., positive control)
[11,12]. Nondependent recreational users of CNS depressants were
selected for participation in the study because they represent the
population at greatest risk of abuse of a compound with potential
sedative effects, and they could provide meaningful ratings of the drug
experiences with a lower risk of false negative results [10,13–15].
2. Material and methods
This Phase I, single-dose, randomized, double-blind, double-dummy,
PBO- and active-controlled crossover study (093–153) was conducted
at a single site in Toronto, Ontario, Canada, in accordance with the
Declaration of Helsinki and the International Conference onHarmoniza-
tion/Good Clinical Practice Guidelines. The study protocol was reviewed
and approved by an Institutional Review Board (Ontario Institutional
Review Board, Aurora, Ontario, Canada), and all subjects provided
written, informed consent prior to study initiation.
2.1. Study population
Subjects were healthymale and female recreational CNS depressant
users aged between 18 and 55 years, with a body mass index (BMI) of
18 to 33 kg/m2 and a minimum weight of 50 kg at screening. They
were required to have had ≥10 nontherapeutic lifetime experiences
with CNS depressants (speciﬁcally, sedative or hypnotic use) includ-
ing at least one nontherapeutic use within the 12 months prior to
screening; the use of subjects with a history of relevant recreational
drug use is consistent with current FDA guidelines for human abuse
liability studies [10]. Female subjects of child-bearing potential
were required to be using an effective form of birth control. All sub-
jects were required to test negative for alcohol and drugs of abuse
prior to dosing in the pharmacologic qualiﬁcation and treatment
phases.
The main exclusion criteria included any history of drug or alcohol
dependence (as per Diagnostic and Statistical Manual of Mental
Disorders criteria and including subjects who had ever entered a drugrehabilitation program), psychiatric or neurological illness, hyponatremia
(serum sodium level ≤ 130 mmol/L), or any condition that may interfere
with drug absorption, distribution, metabolism, or excretion. Subjects
were restricted fromusing other prescription, nonprescription, or recrea-
tional drugs during the study.
2.2. Study design
The study consisted of four phases: screening, pharmacologic
qualiﬁcation, treatment, and follow-up. Randomization was performed
using a computer-generated randomization schedule, and subjects
and clinical research unit staff members were blinded to treatment
assignment by use of identical drug capsules and/or tablets.
Within 28 days of screening, subjects attended a double-blind cross-
over pharmacologic qualiﬁcation session to ensure that they could
discriminate effects of the active control (ALP) compared with those
of PBO. In order to be eligible to enter the treatment phase, subjects
were required to meet the following qualiﬁcation criteria: peak score
in response to ALP N PBO onDrug-Liking VAS (difference of ≥10 points);
acceptable PBO and ALP responses; available safety data at ALP 2.0 mg
consistent with the subject being able to tolerate the ALP 3.0 mg dose
as judged by the investigator or designee; and general behavior sugges-
tive that the subjectwould be able to successfully complete the study, as
judged by the clinic staff.
Thus, subjects were randomized to receive either a single dose of
ALP (2.0 mg) or matching PBO in a double-blind crossover fashion,
separated by a washout period of 24 h. Subjects qualiﬁed to enter the
treatment phase if they met all qualiﬁcation criteria.
The treatment phase consisted of seven 3-day visits, each separated
by a washout interval of at least 7 days. Qualifying subjects were ran-
domly assigned to a predetermined treatment sequence according to a
two 7 × 7 Williams square design (14 sequences in total) and received
a single dose of each of the following in a double-blind, double-
dummy, crossover manner: ESL 800 mg, ESL 1600 mg, ESL 2000 mg,
ESL 2400 mg, ALP 1.5 mg, ALP 3.0 mg, and PBO. The study was
completed when subjects returned for a safety follow-up visit, which
was scheduled 5–10 days after the last administration of study drug.
2.3. Pharmacodynamic assessments
Pharmacodynamic (PD) measures were collected over 24 h
postdosing using validated computerized software (Scheduled
Measurement System, SMS-INC Research, Toronto). Subjects rated per-
ceptions of their subjective state and of the effects of the study drugs,
using “at this moment” and “next-day” VASs, administered as unipolar
and bipolar 100-point scales, as described by Schoedel et al. [16]
(Table 1 lists the test questions and response anchors for each VAS)
and the 49-item Addiction Research Center Inventory (ARCI; each
item answered as True or False, see Martin et al. [17]). The Subjective
Drug Valuemeasure andmeasures for objective assessment of cognitive
and psychomotor function were also administered. Subjects undertook
training and practice sessions on relevant subjective outcomemeasures
at the start of the pharmacologic qualiﬁcation stage and prior to each
treatment session. The primary outcome measure was the bipolar
Drug-Liking VAS. Secondary outcome measures (subjective) included
the unipolar VASs: Take Drug Again, High, Good Effects, Bad Effects,
Any Effects, Dizziness, and Drug Similarity; the bipolar VASs: Overall
Drug-Liking and Alertness/Drowsiness; the ARCI subscales: Morphine–
Benzedrine Group (MBG; euphoria), Pentobarbital Chlorpromazine
Alcohol Group (PCAG; sedation), and Lysergic Acid Diethylamide
Group (LSDG; dysphoria) scales [17]; the Subjective Drug Value (meth-
od adapted from Grifﬁths et al. [18]); and cognitive and psychomotor
function measures: Choice Reaction Time (CRT; as per Milovan et al.
[19]), Divided Attention (DAT) [11,19], and Hopkins Verbal Learning
Task—Revised (HVLT-R) tests [20,21].
Table 1
VAS: test questions and response anchors (bipolar and unipolar scales).
Test question
Response anchors
0 50 100
Bipolar
Drug-Liking At this moment, my liking for this drug is … Strong disliking Neither like nor dislike Strong liking
Overall Drug-Liking Overall, my liking for this drug is … Strong disliking Neither like nor dislike Strong liking
Alertness/Drowsiness My mental state is… Very drowsy Neutral Very alert
Unipolar
Good Effects I can feel good drug effects Deﬁnitely not – Deﬁnitely so
High I am feeling high Deﬁnitely not – Deﬁnitely so
Bad Effects I can feel bad drug effects Deﬁnitely not – Deﬁnitely so
Any Effects I can feel any drug effect Deﬁnitely not – Deﬁnitely so
Dizziness I am feeling dizzy Deﬁnitely not – Deﬁnitely so
Take Drug Again I would take this drug again Deﬁnitely not – Deﬁnitely so
Drug Similarity How similar is the drug you most recently received to [drug name]? Not at all similar – Very similar
VAS, visual analog scales.
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speciﬁcally referring to drug) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and
24 h postdose. Overall Drug-Liking VAS, Take Drug Again VAS, and Sub-
jective Drug Value were assessed at 10 and 24 h postdose, and Drug
Similarity VAS was assessed at 10 h postdose. Choice Reaction Time
and DAT were evaluated predose and at 1, 2, 4, 6, and 10 h postdose,
and HVLT-R was performed predose and 0.5, 3, and 6 h postdose.
2.4. Pharmacokinetic assessments
Pharmacokinetic (PK) samples were collectedwithin approximately
5min of completing the PD assessments. Descriptive statistics were cal-
culated per timepoint for plasma concentrations of ESL, eslicarbazepine,
and (R)-licarbazepine. Concentration-time proﬁles for eslicarbazepine
were analyzed via noncompartmental methods to estimate PK parame-
ters in plasma, according to the model-independent approach. Plasma
eslicarbazepine PK endpoints were the following: maximum observed
plasma concentration (Cmax), time to Cmax (tmax), area under the curve
(AUC) from time zero to the last measurable concentration (AUC0–last),
AUC from time zero to inﬁnity (AUC0–∞), drug half-life (t½), elimination
rate constant (λz), apparent total clearance (CL/F), and apparent volume
of distribution (Vz/F).
2.5. Safety and tolerability
Safety assessments included the following: the incidence, frequency,
and severity of AEs (both spontaneously reported and as determined by
the use of nonleading questions at speciﬁc time points); laboratory pa-
rameters (clinical chemistry, hematology, and urinalysis); and vital
signs, physical examinations, and 12-lead electrocardiograms. Addition-
ally, suicidal behavior was assessed using the Columbia-suicide severity
rating scale (C-SSRS).
2.6. Data analyses
As determined by a paired t-test with a 2-sided signiﬁcance level of
0.05, a sample size of 35 subjects was estimated to have ≥90% power to
detect an 8.4-point difference inDrug-LikingVASpeak score (maximum
effect [Emax]) using an estimated standard deviation (SD) of 14.8 (the
pooled intrasubject SD from PBO, ALP 1.5 mg, and ALP 3 mg data
[22]). Based on an estimated 30% dropout rate, a sample size of 49 sub-
jects was required for randomization to the treatment phase to ensure
data from at least 35 subjects completing all treatments.
Randomized subjects who completed all treatment sessions and had
no major protocol deviations were included in PD analyses. Pharmaco-
kinetic analyses were conducted for the PK population (all randomized
subjectswho received at least one dose of ESL and forwhomat least onePK sample was obtained after dosing and who had no protocol devia-
tions thatwould exclude them from analysis). All subjects who received
at least one dose of study drug during the treatment phase were includ-
ed in the safety evaluation.
All statistical analyses were performed using SAS (version 9.2, SAS
Institute Inc., Cary, NC, USA). Primary and secondary measures were
summarized at each timepoint using descriptive statistics, and point es-
timates, 95% conﬁdence intervals (95% CI) and p-values were generated
for treatment comparisons. The major study endpoint was Emax on the
Drug-Liking VAS, for ESL versus PBO (primary) and ESL versus ALP
(major secondary). For each measure, peak scores (Emax and/or Emin
[minimum effect], as applicable) were analyzed using a linear mixed-
effect analysis of covariance (ANCOVA) which included period,
sequence, and treatment as ﬁxed effects and subject within sequence
as a random effect; predose observation was used as a covariate when
available.
For all endpoints, the assumption on normal distribution of the data
required for ANCOVA model was examined using normality test. If no-
ticeable departures from normality assumptions were detected for
any PD endpoint, nonparametric methods were used. The Friedman's
method was used to test the overall treatment effect, whereas the
Wilcoxon Signed Rank testwas used to compare the pairwise treatment
differences.3. Results
3.1. Subject disposition and baseline characteristics
One hundred and eleven subjects were screened, 83 participated in
the qualiﬁcation session, and 56 met the qualiﬁcation criteria. Of
these, 53 were randomized to the treatment phase, and a total of 44
(83.0%) subjects completed all seven treatment periods of the study
and were included in the PD analyses (see Fig. S1 for details of subject
disposition). A total of nine subjects discontinued the study after
receiving studymedication: four due to AEs, two for administrative rea-
sons, one due to physician decision, one due to noncompliancewith the
study, and one subject withdrew consent.
Of the 53 subjects randomized to the treatment phase, 43 (81.1%)
were male, 49 (92.5%) were white, two were Black or African-
American (3.8%), one was Asian (1.9%), and one was of other race
(1.9%). The mean (SD; range) age of subjects was 37 (9.4; 21–55)
years, and the mean BMI was 25.4 (2.7; 18.1–30.2) kg/m2. In terms of
previous recreational drug use, all 53 subjects had previously used
CNS depressants, and 42 (79.2%), 35 (66.0%), 30 (56.6%), and 9
(17.0%) subjects had previously used cannabinoids, opioids, stimulants,
and hallucinogens, respectively.
Table 2
‘Drug-Liking’ VAS Emax: ANOVA results.a
Pairwise comparison LS mean difference (SE) 95% CI p-Value
ESL vs PBOb
ESL 800 mg vs PBO 3.6 (2.69) −1.8, 8.9 0.1885
ESL 1600 mg vs PBO 9.3 (2.69) 4.0, 14.6 0.0007
ESL 2000 mg vs PBO 12.2 (2.69) 6.9, 17.5 b .0001
ESL 2400 mg vs PBO 13.3 (2.69) 8.0, 18.6 b .0001
ESL versus ALPc
ESL 800 mg vs ALP 1.5 mg −22.9 (2.69) −28.2,−17.6 b .0001
ESL 1600 mg vs ALP 1.5 mg −17.1 (2.69) −22.4,−11.8 b .0001
ESL 2000 mg vs ALP 1.5 mg −14.2 (2.69) −19.5,−8.9 b .0001
ESL 2400 mg vs ALP 1.5 mg −13.1 (2.69) −18.4,−7.8 b .0001
ESL 800 mg vs ALP 3.0 mg −23.2 (2.69) −28.5,−17.9 b .0001
ESL 1600 mg vs ALP 3.0 mg −17.5 (2.69) −22.8,−12.2 b .0001
ESL 2000 mg vs ALP 3.0 mg −14.5 (2.69) −19.8,−9.2 b .0001
ESL 2400 mg vs ALP 3.0 mg −13.5 (2.69) −18.8,−8.2 b .0001
Results of pairwise comparisons between ALP and PBO (p-values) are shown in Table 3.
Bold p values in the table represent signiﬁcance at p ≤ 0.0001.
ALP, alprazolam; ANOVA, analysis of variance; CI, conﬁdence interval; Emax, maximum ef-
fect; ESL, eslicarbazepine acetate; LS, least squares; PBO, placebo; PD, pharmacodynamic;
SE, standard error; VAS, visual analog scale.
a Maximum liking, PD population (n = 44).
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3.2.1. Drug-Liking VAS (primary endpoint)
Mean Drug-Liking VAS scores over 24 h postdose are presented in
Fig. 1A. The dose–response relationship seen with ALP use was relative-
ly ﬂat, whereas ESL was associated with a slightly increasing response
with increasing dose (Fig. 1B).
Drug-Liking VAS Emax valueswere signiﬁcantly higher for both doses
of ALP compared with PBO (least squares [LS] mean differences [95% CI]
were 26.4 [21.1, 31.7] and 26.8 [21.5, 32.1] for ALP 1.5 mg and 3.0 mg,
respectively; p b 0.0001 for both), conﬁrming study validity. Drug-
Liking VAS Emax values for all ESL doses were signiﬁcantly lower com-
pared with those for 1.5 mg and 3.0 mg ALP (for all ESL doses, LS
mean differences ranged from −13.1 to −23.2; all p b 0.0001;
Table 2). Drug-Liking VAS Emax values for the three highest ESL doses
were statistically different from PBO: for ESL 1600 mg, ESL 2000 mg,
and ESL 2400 mg, LS mean differences in Emax were 9.3 (p = 0.0007),
12.2 (p b 0.0001), and 13.3 (p b 0.0001), respectively; whereas, the low-
est dose of ESL 800 mg was not signiﬁcantly different from PBO: LS
mean difference in Emax was 3.6 (p = 0.1885) (Fig. 2 and Table 2).b Primary study endpoint.
c Major secondary endpoint.3.2.2. Overall Drug-Liking VAS, Take Drug Again VAS and Subjective Drug
Value
For end-of-day/next-day measures, some values were signiﬁcantly
higher for ESL than for PBO; primarily at higher ESL doses (2000 mg
and/or 2400 mg) but only for some endpoints (Fig. 2 and Table 3).
Scores for all endpoints for the measures were signiﬁcantly higher for
both doses of ALP than for PBO (Fig. 2 and Table 3). Most endpointsFig. 1. ‘Drug-Liking’ VAS scores: time–response proﬁles and dose–response relationships
for ESL, ALP, and PBO. A) ‘Drug-Liking’ VAS scores (mean ± standard error). (“At this
moment, my liking for this drug is …”); 0 = ‘strong disliking’; 100 = ‘strong liking’;
50 = ‘neither like nor dislike’. B) Dose–response relationship for ‘Drug-Liking’ VAS Emax
(mean ± 95% CI). ALP, alprazolam; CI, conﬁdence interval; Emax, maximum effect; ESL,
eslicarbazepine acetate; PBO, placebo; VAS, visual analog scale.for the measures were signiﬁcantly lower with ESL (all doses) than
with 1.5 mg and 3.0 mg ALP (Table 3).
3.3. Measures of positive effects
3.3.1. Good Effects VAS, ARCI MBG, and High VAS
Mean time–response proﬁles (ESL, ALP, and PBO) on the Good
Effects VAS are presented in Fig. 3A. Good Effects VAS and High VAS
scores were signiﬁcantly higher for ESL (all doses) than for PBO, partic-
ularly at the higher doses. For the ARCI MBG (‘euphoria’) scale, only the
2400mgESL dosewas signiﬁcantly higher than PBO (Fig. 2 and Table 3).
All endpoint measures were signiﬁcantly higher than PBO with both
ALP doses, while ESL (all doses) had signiﬁcantly smaller effects than
ALP (both doses) (Table 3).
3.4. Measures of negative effects
3.4.1. Bad Effects VAS, ARCI LSDG
Mean time–response proﬁles for the Bad Effects VAS are presented
in Fig. 3B. Treatment effects on negative effect measures (Bad Effects
VAS and ARCI LSDG) were modest for all doses of ESL compared with
those of PBO. While statistically signiﬁcant differences from PBO in
Emax were observed for Bad Effects VAS and ARCI LSDG with ESL
2000 mg and 2400 mg (and also with ESL 1600 mg for ARCI LSDG),
the magnitude of these differences was relatively small compared
with the differences observed between ALP and PBO (for Bad Effects
VAS, median differences versus PBO were 0.5 for ESL 2000 mg and 0
for ESL 2400 mg, compared with 31 for ALP 1.5 mg and 40 for ALP
3.0mg; Table 3). Therefore, the clinical relevance of the observed differ-
ences between ESL and PBO is unknown. Negative effects were general-
ly greater with ALP (particularly at 3.0 mg) compared with those of ESL
(Table 3).
3.5. Sedative and other effect measures
3.5.1. ARCI-PCAG, Alertness/Drowsiness VAS, Any Effects VAS, Dizziness VAS,
Drug Similarity VAS
In general, ESL showed greater sedative effects compared with PBO
on the ARCI-PCAG and Alertness/Drowsiness VAS but smaller effects
compared with ALP (Fig. 2 and Table 3). Mean time–response proﬁles
for the Any Effects VAS are presented in Fig. 4A. Any Effects VAS Emax
values for both ALP and ESL were signiﬁcantly greater than for PBO
Fig. 2. Selected subjective measures of abuse liability: ANOVA and signed-rank test results for peak effects (Emax; differences versus PBO)†. †Data are LS mean differences ± 95% CI or
medians of intrasubject differences ± SQR, depending on the distribution of the data. *p b 0.05 versus PBO. ALP, Alprazolam; ANOVA, analysis of variance; ARCI, 49-item Addiction
Research Center Inventory (MBG, Morphine–Benzedrine Group; CI, conﬁdence interval; Emax, maximum effect; ESL, eslicarbazepine acetate; LS, least squares; PBO, placebo; PCAG,
Pentobarbital Chlorpromazine Alcohol Group); SQR, semiquartile range; VAS, visual analog scale.
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icantly greatermean Emax scores for ALP versus ESL, except ESL 2400mg
versus ALP 1.5mg (Fig. 2 and Table 3). Alprazolam and the three higher
ESL doses were associated with greater Dizziness VAS scores than PBO,
but ESL was associated with lower Dizziness VAS scores than ALP
(Table 3). On most secondary measures (e.g., Any Effects VAS; Fig. 4B),
the dose–effect relationship was relatively ﬂat or showed saturation at
the higher doses.Table 3
Secondary PD outcome measures.a
Pairwise
comparison
Emax: LS mean difference (p-value) or median of intrasubj
‘Overall
Drug-Liking’
VASb
‘Take Drug
Again’ VASc
‘Good
Effects’ VASc
ARCI
MBGc
‘Hig
VAS
ALP vs PBO
ALP 1.5 mg vs PBO 19.5⁎⁎⁎ 24.0⁎⁎⁎ 80.5⁎⁎⁎ 4.5⁎⁎⁎ 6
ALP 3.0 mg vs PBO 21.0⁎⁎⁎ 28.5⁎⁎⁎ 72.0⁎⁎⁎ 6.5⁎⁎⁎ 6
ESL versus PBO
ESL 800 mg vs PBO 3.0NS 0.0NS 18.0⁎⁎⁎ 0.0NS 1
ESL 1600 mg vs PBO 5.7NS 2.5NS 15.5⁎⁎⁎ 0.0NS 2
ESL 2000 mg vs PBO 6.5NS 9.0⁎ 49.5⁎⁎⁎ 0.0NS 4
ESL 2400 mg vs PBO 6.1NS 8.0⁎ 48.5⁎⁎⁎ 0.0NS 3
ESL versus ALP
ESL 800 mg vs ALP 1.5 mg −16.5⁎⁎⁎ −19.5⁎⁎⁎ −36.0⁎⁎⁎ −3.0⁎⁎⁎ −4
ESL 1600 mg vs ALP 1.5 mg −13.9⁎⁎⁎ −15.5⁎⁎⁎ −26.5⁎⁎⁎ −3.0⁎⁎⁎ −3
ESL 2000 mg vs ALP 1.5 mg −13.0⁎⁎⁎ −10.0⁎⁎ −21.0⁎⁎⁎ −3.0⁎⁎⁎ −1
ESL 2400 mg vs ALP 1.5 mg −13.5⁎⁎⁎ −6.5⁎⁎ −18.0⁎⁎⁎ −3.0⁎⁎⁎ −2
ESL 800 mg vs ALP 3.0 mg −18.0⁎⁎⁎ −20.0⁎⁎ −35.5⁎⁎⁎ −6.0⁎⁎⁎ −5
ESL 1600 mg vs ALP 3.0 mg −15.4⁎⁎⁎ −18.0⁎⁎⁎ −30.0⁎⁎⁎ −6.5⁎⁎⁎ −4
ESL 2000 mg vs ALP 3.0 mg −14.5⁎⁎⁎ −9.5⁎⁎ −21.0⁎⁎⁎ −7.0⁎⁎⁎ −2
ESL 2400 mg vs ALP 3.0 mg −14.9⁎⁎⁎ −9.0⁎⁎ −16.5⁎⁎⁎ −6.5⁎⁎⁎ −3
ALP, alprazolam; ARCI, 49-ItemAddiction Research Center Inventory (LSDG, Lysergic Acid Dieth
Alcohol Group); Emax, maximum effect; Emin, minimum effect; ESL, eslicarbazepine acetate; LS
NS: not signiﬁcant.
⁎ p b 0.01.
⁎⁎ p b 0.001.
⁎⁎⁎ p b 0.0001.
a PD population (n = 44).
b LS mean difference in Emax (p-value for pairwise comparison).
c Median intrasubject difference in Emax (p-value for pairwise comparison).
d Emin (Emin represents maximum drowsiness).OnDrug Similarity VAS,while ALPwas identiﬁed strongly as a depres-
sant (and to a lesser extent as an opioid), scores for ESL were more mod-
est (Fig. S2). Mean VAS scores indicating similarity with benzodiazepines,
and to a lesser extent codeine/morphine, were higher for ALP than for
PBO (benzodiazepines: ALP 1.5 mg = 91.0, ALP 3.0 mg = 90.0, PBO =
25.5; codeine/morphine: ALP 1.5 mg = 33.8, ALP 3.0 mg = 35.8,
PBO= 9.0). Mean VAS scores indicating similarity with benzodiazepines
were also higher for ESL (800–2400mg=45.4–73.2) than for PBO (25.5).ect difference (p-value)
h’
b
‘Bad
Effects’
VASc
ARCI
LSDGc
ARCI
PCAGb
‘Alertness;
Drowsiness’ VASc,d
Any Drug
Effectsc
‘Dizziness’
VASc
2.0⁎⁎⁎ 31.0⁎⁎⁎ 2.0⁎⁎⁎ 5.5⁎⁎ −31.5⁎⁎⁎ 79.5⁎⁎⁎ 62.0⁎⁎⁎
9.5⁎⁎⁎ 40.0⁎⁎⁎ 4.0⁎⁎⁎ 6.4⁎⁎⁎ −37.5⁎⁎⁎ 80.5⁎⁎⁎ 73.0⁎⁎⁎
8.1⁎ 0.0NS 0.0NS 1.1NS −0.5NS 22.0⁎ 0.0NS
6.7⁎⁎⁎ 0.0NS 0.0⁎ 1.8⁎⁎ −9.5⁎⁎ 31.5⁎⁎⁎ 0.0NS
2.2⁎⁎⁎ 0.5NS 1.0⁎⁎⁎ 3.0⁎⁎⁎ −14.0⁎⁎⁎ 56.5⁎⁎⁎ 4.0⁎⁎⁎
7.6⁎⁎⁎ 0.0NS 0.0⁎⁎ 2.8⁎⁎⁎ −11.5⁎⁎ 51.5⁎⁎⁎ 7.0⁎
3.9⁎⁎⁎ −26.0⁎⁎ −1.5⁎⁎⁎ −4.4⁎⁎⁎ 28.0⁎⁎⁎ −34.5⁎⁎⁎ −42.5⁎⁎⁎
5.3⁎⁎⁎ −20.0⁎⁎ −1.0⁎⁎⁎ −3.7⁎⁎⁎ 16.5⁎⁎⁎ −20.5⁎⁎⁎ −45.5⁎⁎⁎
9.8⁎⁎ −13.0⁎⁎ −1.0⁎ −2.4⁎⁎⁎ 14.0⁎⁎⁎ −7.5⁎⁎⁎ −27.5⁎⁎⁎
4.4⁎⁎⁎ −7.5⁎ −1.0⁎ −2.7⁎⁎⁎ 9.5⁎⁎⁎ −9.0⁎⁎ −24.0⁎⁎⁎
1.4⁎⁎⁎ −34.5⁎⁎⁎ −3.0⁎⁎⁎ −5.3⁎⁎⁎ 29.5⁎⁎⁎ −34.5⁎⁎⁎ −51.5⁎⁎⁎
2.8⁎⁎⁎ −23.0⁎⁎⁎ −3.0⁎⁎⁎ −4.6⁎⁎⁎ 21.0⁎⁎⁎ −18.5⁎⁎⁎ −62.5⁎⁎⁎
7.3⁎⁎⁎ −25.5⁎⁎⁎ −2.0⁎⁎⁎ −3.4⁎⁎⁎ 14.5⁎⁎⁎ −5.0⁎⁎⁎ −35.0⁎⁎⁎
1.9⁎⁎⁎ −21.5⁎⁎ −2.0⁎⁎⁎ −3.6⁎⁎⁎ 15.0⁎⁎⁎ −9.5⁎⁎⁎ −30.0⁎⁎⁎
ylamide Group; MBG, Morphine–Benzedrine Group; PCAG, Pentobarbital Chlorpromazine
, least squares; PBO, placebo; PD, pharmacodynamic; VAS, visual analog scale.
Fig. 3. ‘Good Effects’ and ‘Bad Effects’ VAS scores: time–response proﬁles for ESL, ALP, and
PBO. A) ‘GoodEffects’VAS scores (“I can feel gooddrug effects”). B) ‘Bad Effects’VAS scores
(“I can feel bad drug effects”). Data are mean scores ± SE over time, up to 24 h postdose.
0 = ‘deﬁnitely not’; 100 = ‘deﬁnitely so’. ALP, alprazolam; ESL, eslicarbazepine acetate;
PBO, placebo; SE, standard error; VAS, visual analog scale.
Fig. 4. ‘Any Effects’ VAS scores: time–response proﬁles and dose–response relationships
for ESL, ALP, and PBO. A) ‘Any Effects’ VAS scores (mean ± SE). (“I can feel any drug
effects”); 0 = ‘deﬁnitely not’; 100 = ‘deﬁnitely so’. B) Dose–response relationship for
‘Any Effects’ VAS Emax (mean ± 95% CI). ALP, alprazolam; CI, conﬁdence interval; Emax,
maximum effect; ESL, eslicarbazepine acetate; PBO, placebo; SE, standard error; VAS,
visual analog scale.
68 N. Levy-Cooperman et al. / Epilepsy & Behavior 61 (2016) 63–71The same was true (to a much lesser extent) for similarity with codeine/
morphine (ESL 800–2400 mg = 24.4–33.2; PBO = 9.0); scores for ESL
were nevertheless lower than those for ALP.
3.6. Cognitive and psychomotor effect measures
3.6.1. CRT, DAT, and HVLT-R
Mean CRT total reaction times over 10 h postdose are presented in
Fig. 5A. In terms of DAT and CRT variables, dose-related decreases in
performance (i.e., decreases in manual tracking ability [percentage
over the road; Fig. 5B] and increases in reaction time [Fig. 5C]) were
seen with ALP, starting at 1 h postdose and lasting for at least 6 h
postdose. Eslicarbazepine acetate showed less of an effect on these var-
iables. A similar pattern of effects was observed on percentage correct
responses (CRT) and number of false alarms and percentage target
hits (DAT): decrements in performance were seen with ALP, but there
was little or no effect of ESL (data not shown). Only ALP 3 mg showed
an apparent effect on HVLT-R variables (delayed recall hits, percent re-
tention, recognition discrimination index, and total number of errors),
especially at 3 h postdose, while the effects of the other active treat-
ments were minimal compared with those of PBO (data not shown).
3.7. Pharmacokinetics
Mean Cmax, AUC0–last, and AUC0–∞ increased with increasing ESL
dose; the increases in AUC0–last and AUC0–∞ appeared to be dose propor-
tional. The time to reach Cmax increased with increasing ESL dose, and
the median tmax occurred within approximately 1.6 to 3.1 h postdose,
although it was delayed in some subjects up to 10 h postdose. Median
t½ ranged from 13 to 17 h, and mean CL/F and Vz/F for eslicarbazepine
were consistent across all dose groups.3.8. Safety
Overall, ESL was relatively well tolerated in healthy recreational CNS
depressant users. No deaths or serious AEs (SAEs) occurred during the
study. Four subjects (7.5%) discontinued because of treatment-
emergent AEs (TEAEs), which included an electrocardiogram T-wave
inversion (n=1, ESL 1600mg), an increase in aspartate aminotransfer-
ase (AST; n=1, PBO; n=1, ESL 1600mg), and toothache (n=1, PBO).
During the treatment phase, 22/49 (44.9%; PBO), 48/49 (98.0%; ALP
1.5 mg and 3.0 mg), 27/48 (56.3%; ESL 800 mg), 29/48 (60.4%; ESL
1600 mg), and 37/47 (78.7%; ESL 2000 mg and 2400 mg) had at least
one TEAE (Table 4). Most TEAEs were mild or moderate, and themajor-
ity of events were considered at least possibly related to study drugs.
Somnolence (33.3–51.1%), oral paresthesia (12.5–27.7%), fatigue
(4.2–17.0%), and headache (6.3–12.8%) were the most common TEAEs
associated with ESL doses. Somnolence was the most common TEAE
associated with ALP doses (83.7–89.8%); euphoric mood (14.3–20.4%),
fatigue (16.3–24.5%), and dizziness (6.1–10.2%) were also relatively
common. The most common TEAEs with PBO were somnolence
(20.4%), headache (12.2%), and fatigue (6.1%). Themajority of potential-
ly abuse-related events were sedative-type events (primarily somno-
lence), and the incidence of these events (in particular, somnolence)
was higher with ALP doses than with ESL.
Clinical laboratory values were within normal ranges at all
assessments. However, a number of related TEAEs and abnormalities
were reported. In six subjects, hemoglobin levels were normal at base-
line and abnormally low at follow-up. Other parameters that were nor-
mal at baseline and abnormal at follow-up were the following: plasma
albumin (seven subjects), sodium (six), lactate dehydrogenase (four),
Fig. 5. Changes in CRT and DAT variables over time, for ESL, ALP, and PBO. A) Total CRT
reaction times. B) DAT percentage over the road (manual tracking ability). C) DAT mean
response latencies (reaction time). Data shown are means ± SE over time, up to 10 h
postdose. ALP, alprazolam; CRT, Choice Reaction Time; DAT, Divided Attention; ESL,
eslicarbazepine acetate; PBO, placebo; SE, standard error.
69N. Levy-Cooperman et al. / Epilepsy & Behavior 61 (2016) 63–71AST (three), and urea concentrations (three). AEs related to these pa-
rameters were reported in three subjects. A slight increase in heart
rate and a decrease in blood pressure occurred with ALP, otherwise
mean vital sign values were within normal range (one subject had a
TEAE of increased blood pressure). Mean values for all electrocardio-
gram (ECG) parameters were within normal range, although one sub-
ject experienced an ECG-related TEAE. There were no clinically
signiﬁcant ﬁndings relating to physical examination or C-SSRS during
the study.4. Discussion and conclusions
The study was designed and performed according to guidelines for
the assessment of abuse liability in humans [10,13–15]. In particular,
this study enrolled and randomized recreational drug users with a his-
tory of CNS depressant use who were able to discern between PBOand the active control, ALP. As expected, ALP was associated with
signiﬁcant abuse-related effects compared with PBO, including primary
outcome measures such as Drug-Liking VAS. Consistent with these
ﬁndings, ALP was strongly identiﬁed as a benzodiazepine on the Drug
Similarity VAS and was not identiﬁed as PBO. Together, these ﬁndings
conﬁrm the validity and sensitivity of the study. Notably, when
compared with PBO, both doses of ALP were also associated with
some negative effects as measured on the Bad Effects VAS and ARCI
LSDG scale. The balance of effect measures (e.g., Overall Drug-Liking
VAS) demonstrated that, overall, both ALP doses were ‘liked’. However,
the negative effects seenwith the higher dose of ALPmay have contrib-
uted to the relatively ﬂat dose–response observed for some measures
with ALP.
Based on the overall pattern of responses, in comparison with PBO
and ALP, this study demonstrated that ESL 800mgwas not signiﬁcantly
different from PBO with respect to measures of abuse liability.
Therefore, patients taking this dose of ESL and recreational drug users
experimenting with single 800-mg tablets would not be expected to
experience abuse-related subjective effects. Additionally, the observed
ESL dose–response relationships were relatively shallow or showed
saturation at higher doses for most secondary measures, suggesting
that an appropriate range of doses was evaluated and that further
dose escalation of ESL would not result in substantially greater
subjective effects. The highest dose of ESL approved by the FDA
(1600 mg) [23] and the supratherapeutic doses of ESL (2000 mg and
2400 mg) had detectable subjective effects compared with those of
PBO, as demonstrated by statistical differences on most PD endpoints,
including the primary study endpoint (Drug-Liking VAS Emax). Howev-
er, themagnitude of these differenceswas generally small (e.g., LSmean
difference in Drug-Liking VAS Emax of 9.3 for ESL 1600 mg versus PBO
[p = 0.0007]).
Abuse liability studies of AEDs recently approved by the FDA have
shown no statistically signiﬁcant differences between benzodiazepine-
positive controls and pregabalin [24] or retigabine [25]. Lacosamide
produced euphoria-type subjective responses that differentiated
statistically from placebo at 800 mg; these euphoria-type responses
were statistically indistinguishable from those produced by ALP
[26,27]. By comparison, in the present study, ESL (all four doses)
had signiﬁcantly smaller effects than ALP (both doses) on the prima-
ry endpoint and the vast majority of secondary subjective and objec-
tive endpoints. Our interpretation of these small effects is that they
are unlikely to be clinically signiﬁcant. In terms of the Drug Similarity
VAS, subjects rated ESL as being somewhat similar to benzodiaze-
pines, although this may have been partly attributable to the occur-
rence of sedative-type effects, which are known potential side
effects associated with ESL [3,5] and are common within the AED
class.
Furthermore, preclinical studies have demonstrated a lack of
clinically relevant interactions between eslicarbazepine and gamma-
aminobutyric acid-type A (GABAA) receptors (data on ﬁle, Sunovion
Pharmaceuticals Inc.). In contrast, carbamazepine potentiates chloride
currents in cells expressing human GABAA receptors at clinically rele-
vant concentrations [28]. Positive allosteric modulation of GABAA re-
ceptors associated with drugs such as benzodiazepines and
nonbenzodiazepine sedative hypnotics leads to sedating, anxiolytic,
and hypnotic effects, all of whichmay be reinforced with long-term ex-
posure to these drugs and may therefore contribute to abuse liability
[29]. The absence of GABAA-modulating properties for eslicarbazepine
would therefore be expected to yield lower liabilities related to abuse
liability, particularly in comparison with drugs with known abuse
liability such as the benzodiazepines.
Eslicarbazepine acetate demonstrated impairment on some but not
all of the cognitive and psychomotor performance measures. Some
signiﬁcant differences were observed on the CRT total reaction time,
and scores on the DAT test indicated signiﬁcant differences in mean
hit latency (i.e., slower reaction time) and percentage over the road
Table 4
Frequently occurring treatment-emergent adverse events (TEAEs).
Treatment at onset of AE
Preferred term
PBO
N = 49
n (%)
ALP 1.5 mg
N = 49
n (%)
ALP 3.0 mg
N = 49
n (%)
ESL 800 mg
N = 48
n (%)
ESL 1600 mg
N = 48
n (%)
ESL 2000 mg 
N = 47
n (%)
ESL 2400 mg
N = 47
n (%)
Any TEAE 22 (44.9) 48 (98.0) 48 (98.0) 27 (56.3) 29 (60.4) 37 (78.7) 37 (78.7)
Somnolencea 10 (20.4) 41 (83.7) 44 (89.8) 16 (33.3) 21 (43.8) 24 (51.1) 20 (42.6)
Oral paresthesia 1 (2.0) 0 0 6 (12.5) 9 (18.8) 13 (27.7) 12 (25.5)
Fatigue 3 (6.1) 8 (16.3) 12 (24.5) 3 (6.3) 2 (4.2) 8 (17.0) 8 (17.0)
Headache 6 (12.2) 2 (4.1) 1 (2.0) 5 (10.4) 3 (6.3) 4 (8.5) 6 (12.8)
Euphoric moodb 1 (2.0) 10 (20.4) 7 (14.3) 4 (8.3) 2 (4.2) 2 (4.3) 6 (12.8)
Dizzinessc 0 3 (6.1) 5 (10.2) 2 (4.2) 1 (2.1) 3 (6.4) 5 (10.6)
Nausea 0 2 (4.1) 1 (2.0) 1 (2.1) 0 3 (6.4) 3 (6.4 )
Oral hypoesthesia 0 0 0 0 0 3 (6.4) 4 (8.5)
Paresthesia 1 (2.0) 0 0 1 (2.1) 0 1 (2.1) 4 (8.5)
Dysgeusia 0 0 0 0 1 (2.1) 3 (6.4) 1 (2.1)
Catheter site hematoma 0 0 0 0 0 0 3 (6.4)
Diplopia 0 0 3 (6.1) 0 0 0 0
Disturbance in attentiond 0 3 (6.1) 0 0 0 0 0
Data shown are incidences per group, for TEAEs occurring in ≥5% of subjects in any treatment group (treatment phase; safety population).
Shaded rows indicate potentially abuse-related TEAEs. 
aVerbatim term of primarily ‘somnolence’.
bVerbatim term of ‘euphoria’.
cVerbatim terms included primarily ‘light-headedness’(with various spellings) and ‘dizzy’ or ‘dizziness’. 
dVerbatim terms of ‘mental concentration difficulty’ or ‘poor concentration’.
ALP, alprazolam; ESL, eslicarbazepine acetate; PBO, placebo.
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objectivemeasures, such asHVLT-R, showedno signiﬁcant impairments
of verbal learning or memory by any dose of ESL. In contrast, ALP dem-
onstrated signiﬁcant dose-dependent impairment for the majority of
cognitive endpoints, and these effects were signiﬁcantly greater than
those of ESL. The present ﬁndings in recreational CNS depressant users
are broadly consistentwith the results of an earlier study that examined
the effect of ESL on cognition and psychomotor function in healthy
volunteers [19]. For example, at a dose of ESL 800 mg, CRT LS
mean total reaction time was 936 ms (95% CI: 934–1062), and DAT LS
mean percentage over the road was 69% (95% CI: 59–75 [19]).
Single doses of ESL up to 2400 mg were relatively well tolerated
in healthy recreational CNS depressant users; no deaths or SAEs
were reported during this study, and ESL showed a lower incidence
of AEs compared with ALP, in particular, for the common events of
somnolence and euphoric mood. A higher incidence of paresthesia
and lower incidences of nausea and vomiting with ESL were noted
in the present study (in recreational drug users) compared with
those in previous studies of ESL in healthy volunteers. Abuse-
related AEs were generally consistent with PD measures. Although
some subjects had AEs related to vital signs, ECG, and laboratory
tests, there were no apparent treatment-related effects on these
parameters.
Study limitations include the single-dose design of the study and the
use of subjectivemeasures of drug effects alone rather than in combina-
tion with direct assessments of abuse such as self-administration
models. However, the study design and endpoints are consistent
with relevant guidelines for human abuse liability studies [10]. Fur-
thermore, subjective measures often demonstrate concordancewith other methods of abuse liability assessment [30], and subjects
were blinded to treatment assignment, thus lowering the risk of
detection bias.
In conclusion, this study demonstrated that single doses up to
2400 mg of ESL had less impact on measures of abuse liability than
did ALP in recreational CNS depressant users. Although ESL had detect-
able subjective effects and showed some drug-‘liking’ at higher doses,
the magnitude of these effects was small.
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